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Effectiveness of typhoid conjugate vaccine against cultureconfirmed Salmonella enterica serotype Typhi in an
extensively drug-resistant outbreak setting of Hyderabad,
Pakistan: a cohort study
Mohammad Tahir Yousafzai, Sultan Karim, Sonia Qureshi, Momin Kazi, Hina Memon, Amber Junejo, Zohra Khawaja, Najeeb Ur Rehman,
Muhammad Sajid Ansari, Rafey Ali, Ikram Uddin Ujjan, Heera Mani Lohana, Naveed M Memon, Mudassar Hussain, Roohi Nigar, Naor Bar-Zeev,
Farah Naz Qamar

Summary

Background Salmonella enterica serotype Typhi (S Typhi) is a major public health problem in low-income and middleincome countries. We aimed to investigate the effectiveness and impact of the typhoid conjugate vaccine Typbar-TCV
against S Typhi among children in an outbreak setting of extensively drug-resistant (XDR) S Typhi in Pakistan.
Methods This cohort study was done from Feb 21, 2018, to Dec 31, 2019. A census survey of all households located in
the Qasimabad and Latifabad subdistricts of Hyderabad, Pakistan, was done at baseline, and 174 005 households were
registered in the census. The Typbar-TCV immunisation campaign was initiated at temporary vaccination centres and
207 000 children aged 6 months to 10 years were vaccinated from Feb 21, 2018, to Dec 31, 2018. Social mobilisers
informed parents about the vaccination process. Vaccination records were maintained electronically and linked with
the household census surveys. Active surveillance for suspected and blood-culture-confirmed S Typhi was established
in hospitals, clinics, and laboratories to assess the following outcomes: cases of suspected typhoid fever, cultureconfirmed S Typhi, and antimicrobial resistance. An age-stratified cohort of 1100 vaccinated children was randomly
selected from the vaccination registry, tested for Vi-IgG antibodies (data not reported), and followed up fortnightly (via
telephone calls or household visits) until Dec 31, 2019, for ascertainment of outcomes during the study period.
20 847 vaccinated and unvaccinated children were randomly selected from the census registry as a quality control
cohort and followed up from Oct 1 to Dec 31, 2019, for ascertainment of outcomes. Vaccine effectiveness against
suspected, culture-confirmed, and XDR S Typhi was calculated.
Findings 23 407 children from the census registry and surveillance system were included in the vaccine effectiveness
analysis. 13 436 (57·4%) children were vaccinated, 12 214 (52·2%) were male, and 10 168 (43·4%) were aged
6–59 months. 5378 (23·0%) of 23 407 children had suspected S Typhi, among whom 775 (14·4%) had cultureconfirmed S Typhi and 361 (68·6%) of 526 had XDR S Typhi. Vaccine effectiveness was 55% (95% CI 52–57) against
suspected S Typhi (regardless of culture confirmation), 95% (93–96) against culture-confirmed S Typhi, and
97% (95–98) against XDR S Typhi.
Interpretation Typbar-TCV is effective in protecting children against S Typhi infection in an outbreak setting, and was
able, with moderate deployment, to curtail a major XDR S Typhi outbreak in a densely populated setting. The vaccine
shows efficacy against S Typhi irrespective of antimicrobial resistance.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Typhoid fever is a serious public health issue in lowincome and middle-income countries across Africa and
south Asia. More than 90% of the morbidity and mortality
related to enteric fever occurs in Asia, predominantly
among children aged younger than 15 years. In addition
to the high disease burden of typhoid fever, multidrug
resistance (resistance or intermediate resistance to
ampicillin, chloramphenicol, and co-trimoxazole) and
extensive drug resistance (multidrug resistance along
with resistance to fluoroquinolone and third-generation
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cephalosporins)1–3 to Salmonella enterica serotype Typhi
(S Typhi) are a growing threat.3
S Typhi is mainly acquired from contaminated water,
which is now a ubiquitous challenge in many regions
as a result of rapid urbanisation. Another important
source is person-to-person transmission through
food handlers, especially chronic carriers of S Typhi.4
Improvements in water and sanitation infrastructure
and in food safety require major investments, but at
present there is little imminent progress anticipated
within these domains in endemic countries. Vaccination
e1154
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Research in context
Evidence before this study
We did an advanced literature search on PubMed and Google
Scholar using the key terms “TCV” OR “typhoid conjugate
vaccine” OR “Typbar-TCV” OR “typhoid vaccine” AND
“effectiveness” OR “impact” OR “efficacy” for studies published
up to May 30, 2020. Studies unrelated to the typhoid
conjugate vaccine were excluded. A double-blind, placebocontrolled, randomised trial of the typhoid conjugate vaccine
Vi-rEPA (Vi bound to non-toxic recombinant Pseudomonas
aeruginosa exotoxin A) in children aged 2–5 years in Vietnam
reported that two doses of the vaccine had a protective efficacy
of 91·5% (95% CI 77·1–96·6) against culture-confirmed
Salmonella enterica serotype Typhi (S Typhi) at 27 months;
however, this vaccine is not prequalified by WHO. Typbar-TCV is
the only typhoid conjugate vaccine prequalified by WHO.
A phase 3 randomised controlled trial of Typbar-TCV in Nepal
reported a 1-year protective efficacy of 82% with a single dose
of the vaccine in children aged 9 months to 16 years. However,
more studies are needed to establish the real-world impact and
effectiveness of Typbar-TCV—ie, as part of a population-based
immunisation campaign in an outbreak setting.

culture-confirmed drug-resistant and culture-sensitive
S Typhi in children aged 6 months to 10 years in a populationwide campaign setting in Hyderabad, Pakistan. Mass
immunisation with Typbar-TCV resulted in a significant
reduction in culture-confirmed S Typhi cases during the peak
monsoon seasons of 2018 and 2019, demonstrating the
impact of vaccination in protecting against increased
community transmission of S Typhi during the peak
monsoon season.
Implications of all the available evidence
Typbar-TCV is effective against culture-confirmed S Typhi in
children aged 6 months to 10 years in an outbreak setting in
Pakistan and, with only moderate deployment, was able to
curtail an extensively drug-resistant S Typhi outbreak in a
densely populated setting. The vaccine is effective against
S Typhi irrespective of antimicrobial resistance. Typbar-TCV
can therefore be an important tool to control drug-resistant
S Typhi outbreaks. Furthermore, on the basis of these
findings, incorporation of Typbar-TCV into routine
immunisation programmes in endemic countries is highly
recommended.

Added value of this study
In this cohort study, we found that a single dose of TypbarTCV was highly effective (vaccine effectiveness >90%) against

against S Typhi therefore offers the best approach for
disease control.
Older typhoid vaccines, including a single dose of
the intramuscular Vi-polysaccharide and three-dose oral
Ty21a vaccine, have suboptimal efficacy, a short duration
of protection, and cannot be administered to children
younger than 2 years.5,6 However, the new typhoid
conjugate vaccine (Typbar-TCV; Bharat Biotech Inter
national; Hyderabad, India) has shown promising efficacy
in phase 2b and phase 3 trials.7,8 Moreover, it can be given
to children from 6 months of age and is prequalified by
WHO.9 A human challenge study of Typbar-TCV among
adult volunteers in the UK reported a vaccine efficacy of
54·6% against S Typhi bacteraemia.7 The results of the
phase 3 trial of Typbar-TCV in Nepal showed a vaccine
efficacy of 81·6% in children aged 9 months to 16 years.8
However, population-based observational studies are
urgently needed to estimate the effectiveness of TypbarTCV in settings with antimicrobial resistance.
In November, 2016, the Aga Khan University Hospital,
Karachi, Pakistan, identified an emergent extensively
drug-resistant (XDR) S Typhi outbreak in Hyderabad,
Pakistan.10 A large-scale vaccination campaign was
initiated to interrupt transmission. We aimed to
determine the public health impact and effectiveness
of Typbar-TCV in preventing blood-culture-confirmed
S Typhi in children aged 6 months to 10 years, living in
the outbreak areas of Hyderabad, Pakistan.
e1155

Methods

Study design and setting
This cohort study was done from Feb 21, 2018, to
Dec 31, 2019, in the Qasimabad and Latifabad subdistricts
of Hyderabad, Pakistan. The total population of
Hyderabad is around 2·2 million, with 44% of the
population (977 000) living in these two subdistricts.10
Hyderabad is composed of a mixture of a middle-class
and high-density urban slum population. Details of the
study setting have been published,11 and details of the
study are summarised in figure 1.

Baseline census and surveillance
We did a census survey of all households located in
the Qasimabad and Latifabad subdistricts of Hyderabad.
Each household was assigned a unique identifier.
On the day of the visit, global positioning system
(GPS) coordinates and the number, names, sex, and date
of birth of children aged 6 months to 10 years living in
each household and the name of the head of the
household were recorded. Each child was assigned a
unique identifier. Households located in apartments
or residential compounds were assigned a single GPS
coordinate. Non-responsive households were revisited
at the end of the day or a catch-up visit was made on the
following day. Following these attempts, non-responding
households were assigned an identifier and GPS
coordinates, and coded as locked or non-responding.
www.thelancet.com/lancetgh Vol 9 August 2021
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174 005 households were registered in the census. This
census registry served as the data frame linking all
subsequent records from the other components of the
study, including Typbar-TCV vaccination status during
the immunisation campaign, and the surveillance
system.
A detailed description of the surveillance system
and case definition for suspected and culture-confirmed
S Typhi has been published.12,13 Briefly, we established
active surveillance for identification of suspected and
blood-culture-confirmed S Typhi at 13 sentinel sites, in
all major hospitals and clinics of general practitioners
(GPs) in the two subdistricts. Patients presenting to these
sentinel sites with persistent fever for 3 or more days
without any focus of infection were considered to have
suspected typhoid fever, whereas those with a positive
blood culture for S Typhi were recorded as having
culture-confirmed S Typhi infection. Training on case
definitions, the target population, and details of the
study was provided to at least one focal physician at
each sentinel site. A trained research assistant visited
each facility daily to ensure cases were not missed.
Patients with suspected S Typhi were offered free blood
culture testing at the nearest Aga Khan University
Hospital clinical laboratory collection point in Hyderabad,
Pakistan. We also included cases of culture-confirmed
S Typhi from two major laboratories in Hyderabad: the
clinical laboratory of Aga Khan University Hospital and
that of Liaquat University of Medical Health Sciences,
Hyderabad, Pakistan. The surveillance system captures
the whole population of Latifabad and Qasimabad.

Participants and procedures
We began a population-based immunisation cam
paign using Typbar-TCV in children aged 6 months to
10 years living in Qasimabad and Latifabad. All eligible
children were offered free, voluntary vaccination,
and 207 000 children were vaccinated at temporary
vaccination centres from Feb 21, 2018, to Dec 31, 2018.11
With every vaccine dose administered, we recorded the
recipient’s name, age or date of birth (or both), sex,
household and child identifier, date of vaccination,
injection site, vial batch number, and history of previous
typhoid vaccination. The immuni
sation record was
linked to the baseline census registry through unique
household and child identifiers.
We randomly selected an age-stratified subcohort
of 1100 vaccinated children and followed them up from
the day of vaccination until Dec 31, 2019. We used
systematic random sampling with replacement to select
every fifth child in each age group (150 children each
aged 6–11 months, 12–23 months, 24–35 months,
36–47 months, and 48–59 months, and 70 children each
aged 60–71 months, 72–83 months, 84–95 months,
96–107 months, and 108–120 months) visiting the tem
porary vaccination centres. This cohort was periodically
followed up (at 28–42 days, 6 months, 1 year, and 2 years)
www.thelancet.com/lancetgh Vol 9 August 2021

174 005 households (with 222 100 eligible children aged 6 months to 10 years)
identified in baseline census of Qasimabad and Latifabad (Hyderabad,
Pakistan); 207 000 children vaccinated with Typbar-TCV

20 847 children in quality
control cohort

1100 children in vaccinated
subcohort for intensive
follow-up

757 lost to follow-up

20 090 children included in
vaccine effectiveness
analysis: 3047
suspected cases and
99 culture-confirmed
positive cases of S Typhi

42 lost to follow-up

1058 children included in
vaccine effectiveness
analysis: 72 suspected
cases and no
culture-confirmed
positive cases of S Typhi

2259 children identified from
sentinel and laboratory
surveillance:
1583 suspected cases and
676 culture-confirmed
positive cases of S Typhi

23 407 children included in vaccine effectiveness analysis

Figure 1: Study flow diagram
S Typhi=Salmonella enterica serotype Typhi. Participants were followed up from the date of the census survey or
vaccination until Dec 31, 2019.

for serial measurement of serum antibody concen
trations against S Typhi Vi-IgG (data not reported), and
fortnightly telephone calls were made by the research
assistants to enquire about history of illness, including
fever or admission to hospital, or both, during the past
2 weeks. Data on the immunogenicity of Typbar-TCV
will be published at a later date, once all blood samples
have been analysed for Vi-IgG concentrations. Where
febrile illness was identified, the research medical
officer visited the household to examine the child and
collect further clinical details, a hospital discharge
summary, and laboratory tests (if available), and to
establish whether the child fulfilled the case definition
for suspected typhoid fever or culture-con
firmed
S Typhi. Any child with a fever for 3 or more days at
the time of the telephone call was provided free blood
culture testing at the nearest Aga Khan University
Hospital clinical laboratory collection point. Cases were
cross-checked with surveillance data to avoid duplicates.
We randomly selected another quality control cohort of
20 847 children using simple random sampling without
replacement from the baseline census and followed
them up until Dec 31, 2019. From Oct 1 to Dec 31, 2019,
trained research assistants visited the households to
interview parents and collect information about the
history of fever, suspected typhoid fever, and laboratory
testing for S Typhi (blood culture, Typhidot), and
hospital admissions from the date of baseline census or
Typbar-TCV vaccination until the date of the interview.
Information about age, sex, and vaccination status was
available from the census registry. Information about
laboratory testing, prescriptions or hospital discharge
e1156
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Vaccinated
(n=13 436)

Unvaccinated
(n=9971)

Total
(n=23 407)

Study component
Surveillance registry
Case cohort
Vaccinated subcohort

216 (1·6%)

2043 (20·5%)

2259 (9·7%)

12 162 (90·5%)

7928 (79·5%)

20 090 (85·8%)

1058 (7·9%)

··

1058 (4·5%)

Area of residence in Hyderabad, Pakistan
Qasimabad

5382 (40·1%)

4330 (43·4%)

9712 (41·5%)

Latifabad

8054 (59·9%)

5641 (56·6%)

13 695 (58·5%)

Male

7010 (52·2%)

5204 (52·2%)

12 214 (52·2%)

Female

6426 (47·8%)

4767 (47·8%)

11 193 (47·8%)

6–59 months

5521 (41·1%)

4647 (46·6%)

10 168 (43·4%)

60–120 months

7915 (58·9%)

5314 (53·4%)

13 239 (56·6%)

1969 (14·7%)

3409 (34·2%)

5378 (23·0%)

Sex

Age groups

Overall typhoid fever cases
Blood culture tests (n=5378)
Yes

320/1969 (16·3%)

2176/3409 (63·8%)

2496/5378 (46·4%)

No

1649/1969 (83·7%)

1233/3409 (36·2%)

2882/5378 (53·6%)

273/320 (85·3%)

1448/2176 (66·5%)

1721/2496 (69·0%)

47/320 (14·7%)

728/2176 (33·5%)

775/2496 (31·0%)

Blood culture result (n=2496)
Negative
Positive for S Typhi
XDR status (n=775)
6/47 (12·8%)

205/728 (28·2%)

211/775 (27·2%)

XDR

Non-XDR

18/47 (38·3%)

426/728 (58·5%)

444/775 (57·3%)

Results not known

23/47 (48·9%)

97/728 (13·3%)

120/775 (15·5%)

Data are n (%) or n/N (%). S Typhi=Salmonella enterica serotype Typhi. XDR=extensively drug-resistant.

Table 1: Descriptive characteristics of participants included in vaccine effectiveness analysis (n=23 407)

summary (if available), or both, was also recorded.
Cases were cross-checked with surveillance system
records to remove any duplicates. Cases were defined as
suspected typhoid fever or culture-confirmed S Typhi on
the basis of clinical diagnosis by clinicians working at
the sentinel hospitals or, where applicable, laboratory
confirmation of blood cultures. The quality control
cohort thus provided evidence that cases of suspected
typhoid fever and culture-confirmed S Typhi were not
missed as outcomes by the surveillance system.
We developed an electronic data capture programme
using Java structured query language (SQL) platforms as
a database for real-time data collection. Data were synced
to a central server at the Aga Khan University. Dedicated
staff (NUR and RA) carried out quality assurance and
quality control checks to identify illogical responses
and a weekly quality assurance and quality control
report was provided to the research supervisor (SK) in
Hyderabad for field verification. Children who were
missed during the baseline census were assigned new
registration numbers whenever they were encountered
by field staff, and their records were assigned to their
respective household identifier. We linked datasets
from the typhoid surveillance, vaccinated cohort, quality
control cohort, and vaccination registry with the baseline
e1157

census using the household identifier and children’s
unique identifiers.
Ethical approval was obtained from the ethical review
committee of Aga Khan University Karachi (ERC number
2020-1563-14158) and the National Bioethics Committee
of Pakistan (4-87/NBC-323/18/551). Written informed
consent was obtained from one of the parents or legal
guardians at the time of enrolment into the study.

Outcomes
The outcomes of interest were the development of
suspected typhoid fever (irrespective of blood culture),
culture-confirmed S Typhi (irrespective of antimicrobial
resistance), culture-confirmed XDR S Typhi, and nonXDR S Typhi (sensitive to ceftriaxone with or without
multidrug resistance or fluoroquinolone resistance, or
both) among age-eligible unvaccinated children and
those vaccinated with a single dose of Typbar-TCV.

Statistical analysis
We analysed data using Stata, version 15. The vaccinated
cohort and quality control cohort were merged with
the surveillance records for this analysis. Since the vacci
nation campaign and baseline registration of households
occurred on the same day in each neighbourhood, the
person-time at risk for each child was calculated from
the date of vaccination (for vaccinated children) or the
date of baseline registration (for unvaccinated children)
to the date of suspected typhoid fever or cultureconfirmed S Typhi (for children with an outcome) or the
end of study follow-up (Dec 31, 2019) or death or loss to
follow-up, whichever occurred first. Incidence rates with
their corresponding incidence rate ratio (IRR) and
95% CIs were calculated. We excluded any cases of
typhoid fever that occurred less than 28 days after
vaccination from the calculation of vaccine effectiveness.
Vaccine effectiveness, with 95% CIs, against cultureconfirmed, culture-negative suspected, and XDR S Typhi
was calculated as follows: 100 × (1–IRR). Cox regression
analysis was done to measure the hazard ratio (HR) of
developing culture-confirmed S Typhi when adjusted for
age, sex, and residential area. Kaplan-Meier curves
were also plotted to compare the risk of developing
culture-confirmed S Typhi among vaccinated versus
unvaccinated children, children aged 6–59 months
versus those aged 60–120 months, children living in
Latifabad versus those living in Qasimabad, and being
male versus female. Two-sided p values were calculated
with the log-rank test to estimate statistically significant
differences between the Kaplan-Meier curves for each
variable. We measured the impact of Typbar-TCV by
calculating the differences in quarterly cumulative
incidence of culture-confirmed S Typhi before (2017)
and following (2018–19) the vaccination campaign. No
imputation was done for missing information, and
participants with missing details for any variable were
labelled as “unknown”.
www.thelancet.com/lancetgh Vol 9 August 2021
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The sample size was calculated with OpenEpi, version 3,
for cohort design. Assuming the incidence of cultureconfirmed S Typhi among unvaccinated children aged
6 months to 15 years is 455 per 100 000,3 and assuming
50% vaccine coverage, in order to detect a vaccine
effectiveness of at least 55% against culture-confirmed
S Typhi8 with 80% power and 95% CIs, using the χ² test
with continuity correction and after adjusting for a nonresponse rate of 15%, the required minimum sample size
was 20 847 for the quality control cohort. We did not do

any sample size calculation for the subset of the vaccinated
cohort for continuous fortnightly follow-ups. The vacci
nated subcohort was arbitrarily selected primarily for
immunogenicity assessment at several timepoints and
periodically followed up for ascertainment of an outcome.

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.

Total person- S Typhi incidence; number of cases S Typhi incidence; number of
Number of At-risk
participants population time at risk, per 100 000 population (95% CI)
cases per 100 000 person-years
years*
(n)
(n)
(95% CI)

S Typhi incidence
rate ratio (95% CI)

Vaccine effectiveness*
(95% CI)

Both culture-confirmed and suspected S Typhi cases
Age 6–59 months
Vaccinated
Unvaccinated

940

5521

8646

17 025·9 (16 034·4–18 017·4)

10 872·2 (10 643·0–11 101·3)

1653

4647

7599

35 571·3 (34 194·9–36 947·8)

21 752·1 (21 263·0–22 241·1)

0·50 (0·46–0·54)
··

50·0 (45·8–53·9)
··

Age ≥5 years
Vaccinated

1029

7915

12103

13 000·6 (12 259·7–13 741·5)

Unvaccinated

1756

5324

8722

32 982·7 (31 719·8–34 245·6)

8502·2 (8350·7–8653·6)

Vaccinated

1969

13436

20749

14 654·7 (14 056·7–15 252·7)

9489·7 (9360·6–9618·9)

Unvaccinated

3409

9971

16322

34 189·1 (33 258·1–35 120·2)

20 886·3 (20 565·9–21 206·7)

918

5521

8646

16 627·4 (15 645·3–17 609·6)

10 617·7 (10 393·9–10 841·5)

1304

4647

7599

28 061·1 (26 769·3–29 352·9)

171 59·5 (16 773·7–17 545·3)

20 132·0 (19 709·5–20 554·5)

0·42 (0·39–0·46)
··

57·8 (54·4–60·9)
··

Overall
0·45 (0·43–0·48)
··

54·6 (52·0–57·0)
··

Suspected typhoid fever cases
Age 6–59 months
Vaccinated
Unvaccinated

0·62 (0·57–0·67)
··

38·1 (32·6–43·2)
··

Age ≥5 years
Vaccinated

1004

7915

12 103

12 684·8 (11951·6–13 418·0)

8295·6 (8147·8–8443·4)

Unvaccinated

1377

5324

8722

25 864·0 (24 687·8–27 040·3)

15 786·9 (15 455·6–16 118·2)

Vaccinated

1922

13 436

20 749

14 304·9 (13 712·8–14 896·9)

Unvaccinated

2681

9971

16 322

26 888·0 (26 017·7–27 758·3)

22

5521

8646

349

4647

7599

0·53 (0·48–0·57)
··

47·5 (43·0–51·6)
··

Overall
9263·2 (9137·2–9389·2)
16 426·0 (16 174·0–16 678·0)

0·56 (0·53–0·60)
··

43·6 (40·2–46·8)
··

Culture-confirmed S Typhi cases
Age 6–59 months
Vaccinated
Unvaccinated

398·5 (232·3–564·7)
7510·2 (6752·4–8268·0)

254·5 (249·1–259·8)
4592·5 (4489·3–4695·8)

0·06 (0·03–0·09)
··

94·5 (91·5–96·6)
··

Age ≥5 years
Vaccinated
Unvaccinated

25

7915

12 103

379

5324

8722

315·9 (192·2–439·5)

47

13436

20 749

349·8 (250·0–449·6)

226·5 (223·4–229·6)

728

9971

16 322

7301·2 (6790·5–7811·8)

4460·3 (4391·9–4528·8)

14

5521

8646

253·6 (120·9–386·2)

161·9 (158·5–165·3)

220

4647

7599

4734·2 (4123·6–5344·8)

2895·0 (2829·9–2960·1)

7118·7 (6428·0–7809·4)

206·6 (202·9–210·2)
4345·1 (4253·9–4436·3)

0·05 (0·03–0·07)
··

95·2 (92·9–97·0)
··

Overall
Vaccinated
Unvaccinated

0·05 (0·04–0·07)
··

94·9 (93·2–96·3)
··

XDR S Typhi cases
Age 6–59 months
Vaccinated
Unvaccinated

0·06 (0·03–0·10)
··

94·4 (90·4–97·0)
··

Age ≥5 years
Vaccinated
Unvaccinated

4

7915

12 103

206

5324

8722

18

13 436

20 749

426

9971

16 322

50·5 (1·0–100·1)
3869·3 (3351·2–4387·3)

33·1 (32·5–33·6)
2361·7 (2312·2–2411·3)

0·01 (0·00–0·04)
··

98·6 (96·4–99·6)
··

Overall
Vaccinated
Unvaccinated

134·0 (72·1–195·8)
4272·4 (3875·4–4669·3)

86·8 (85·6–87·9)
2610·0 (2570·0–2650·1)

0·03 (0·02–0·05)
··

96·7 (94·7–98·0)
··

(Table 2 continues on next page)
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Total person- S Typhi incidence; number of cases S Typhi incidence; number of
Number of At-risk
participants population time at risk, per 100 000 population (95% CI)
cases per 100 000 person-years
years*
(n)
(n)
(95% CI)

S Typhi incidence
rate ratio (95% CI)

Vaccine effectiveness*
(95% CI)

0·02 (0·00–0·07)

98·1 (93·1–99·8)

(Continued from previous page)
Non-XDR S Typhi cases
Age 6–59 months
Vaccinated
Unvaccinated

2

5521

8646

94

4647

7599

36·2 (-14·0–86·4)

23·1 (22·6–23·6)

2022·8 (1618·0–2427·6)

1237·0 (1209·1–1264·8)

··

··

Age ≥5 years
Vaccinated
Unvaccinated

4

7915

12103

111

5324

8722

6

13 436

20 749

205

9971

16 322

50·5 (1·0–100·1)

33·1 (32·5–33·6)

2084·9 (1701·1–2468·7)

1272·6 (1245·9–1299·3)

0·03 (0·01–0·07)
··

97·4 (93·2–99·3)
··

Overall
Vaccinated
Unvaccinated

44·7 (8·9–80·4)

28·9 (28·5–29·3)

2056·0 (1777·4–2334·5)

1256·0 (1236·7–1275·3)

0·02 (0·01–0·05)
··

97·7 (94·9–99·2)
··

IRR=incidence rate ratio. S Typhi=Salmonella enterica serotype Typhi. XDR=extensively drug resistant. *Calculated as follows: (1 – IRR) × 100.

Table 2: Distribution of vaccination status and vaccine effectiveness against S Typhi

Univariable hazard
ratio (95% CI)

p value

Multivariable hazard p value
ratio (95% CI)

Vaccinated

0·05 (0·04–0·07)

<0·0001

0·05 (0·04–0·07)

Unvaccinated

1 (ref)

Vaccine status
··

1 (ref)

<0·0001
··

Age groups
6–59 months

1·17 (1·02–1·35)

60–120 months

1 (ref)

0·028
··

1·07 (0·93–1·23)
1 (ref)

0·346
··

Sex
Male

1·16 (1·004–1·33)

Female

1 (ref)

0·044
··

1·15 (1–1·33)
1 (ref)

0·050
··

Area of residence in Hyderabad, Pakistan
Qasimabad

0·84 (0·73–0·97)

Latifabad

1 (ref)

0·014
··

0·88 (0·77–1·02)
1 (ref)

0·083
··

S Typhi=Salmonella enterica serotype Typhi.

Table 3: Univariable and multivariable Cox regression analysis for assessment of culture-confirmed S Typhi

Results

See Online for appendix
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24 206 children from the census registry and surveillance
system were selected for this study; after removing
799 (3·3%) non-responders, 23 407 children were included
in the vaccine effectiveness analysis (figure 1). Of these
23 407 children, 13 436 (57·4%) were vaccinated with
Typbar-TCV (table 1). The Latifabad subdistrict accounted
for 13 695 (58·5%) of children included in the study and
the remainder were from Qasimabad. 12 214 (52·2%)
children were male, and 10 168 (43·4%) were aged
6–59 months. 5378 (23·0%) of 23 407 children were
identified to have suspected typhoid fever, of whom
2496 (46·4%) were tested for blood culture and 775 (31·0%)
of 2496 were positive for S Typhi. Information about
antimicrobial sensitivity was available for 655 (84·5%) of
these 775 children, of whom 444 (57·3%) had XDR S Typhi.
Overall, the incidence of suspected typhoid fever was
9490 (95% CI 9361–9619) per 100 000 person-years

among vaccinated children and 20 886 (20 566–21 207)
per 100 000 person-years among unvaccinated children.
The IRRs comparing vaccinated and unvaccinated
children with suspected (regardless of culture) S Typhi,
culture-negative suspected S Typhi, culture-confirmed
S Typhi, XDR S Typhi, and non-XDR S Typhi are shown
in table 2. Vaccine effectiveness was 55% (95% CI 52–57)
against suspected S Typhi (regardless of culture),
44% (40–47) against culture-negative suspected S Typhi,
95% (93–96) against culture-confirmed S Typhi,
97% (95–98) against XDR S Typhi, and 98% (95–99)
against non-XDR S Typhi.
The HR of culture-confirmed S Typhi among vaccinated
children versus unvaccinated children, adjusted for age,
sex, and area of residence, was 0·05 (95% CI 0·04–0·07;
p<0·0001; table 3). Kaplan-Meier plots also showed a
significantly lower risk of culture-confirmed S Typhi
among vaccinated children than among unvaccinated
children (p<0·0001), in children aged 60–120 months
than in those aged 6–59 months (p=0·028), in children
living in Latifabad versus those living in Qasimabad
(p=0·016), and in girls versus boys (p=0·044; figure 2).
Throughout the epidemic (2017–19), the highest
number of non-XDR S Typhi cases was reported in 2017,
followed by a decline in 2018 and then another rise
during July–August, 2019 (appendix p 2). The interrupted
time-series plot of XDR and non-XDR S Typhi cases
showed a slight decline in 2019 compared to 2017 (before
the intervention; appendix p 3). Overall, we observed a
significant decline in cumulative incidence between
2017 (the reference period) and 2018, and between 2017
and 2019, except during October–December in 2017–19,
when a significant rise in incidence was observed
(appendix p 4).

Discussion
As Typbar-TCV was prequalified by WHO in
October, 2017,9 its post-licensure population impact
www.thelancet.com/lancetgh Vol 9 August 2021
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B
Vaccinated
Unvaccinated

Participants with culture-confirmed
S Typhi (%)

Participants with culture-confirmed
S Typhi (%)

A
10
8
6
4
2
0

0

4

8

12

16

Follow-up time (months)

Number at risk
(number of S Typhi cases)
Vaccinated 13426 13418 13408 13369
(0)
(8)
(10)
(9)
9722
9541
Unvaccinated 9968 9877
(0)
(77)
(120) (142)

10215
(12)
9352
(143)

5800
(7)
6518
(196)

4
2

0

4

8

12

16

20

Follow-up time (months)
8612
10112 10034 9937
(70)
(65)
(61)
(41)
13183 13096 12973 10955
(69)
(81)
(90)
(44)

5663
(100)
6655
(103)

D
Qasimabad
Latifabad

Participants with culture-confirmed
S Typhi (%)

Participants with culture-confirmed
S Typhi (%)

6

Number at risk
(number of S Typhi cases)
6–59 months 10161
(0)
60–120 months 13233
(0)

C
10
8
6
4
2
0

8

0

20

6–59 months
60–120 months

10

0

4

8

12

16

20

Follow-up time (months)

Number at risk
(number of S Typhi cases)
9651 9566 9458
Qasimabad 9701
(0)
(44)
(60)
(70)
Latifabad 13693 13644 13564 13452
(0)
(41)
(70)
(81)

8370
(76)
11197
(79)

Male
Female

10
8
6
4
2
0

0

4

8

12

16

20

Follow-up time (months)

5730
(97)
6588
(106)

Number at risk
(number of S Typhi cases)
Male 12209 12158 12065 11945 10181
(0)
(45)
(73)
(85)
(88)
Female 11185 11137 11065 10965 9386
(0)
(40)
(57)
(66)
(67)

6377
(120)
5941
(83)

Figure 2: Survival analysis of culture-confirmed S Typhi cases
(A) Vaccinated versus unvaccinated children. (B) Children aged 6–59 months versus those aged 60–120 months. (C) Area of residence in Hyderabad, Pakistan
(Qasimabad vs Latifabad). (D) Male versus female cases. S Typhi=Salmonella enterica serotype Typhi.

and effectiveness data have not yet been extensively
reported.
This population-based, large-scale, prospective cohort
study, done in a setting with an ongoing XDR
S Typhi outbreak, demonstrates the effectiveness of
Typbar-TCV against culture-confirmed S Typhi. The
effectiveness of Typbar-TCV was 95% against cultureconfirmed S Typhi and 55% against suspected S Typhi
(regardless of culture). Vaccine effectiveness against
XDR S Typhi was 97%. The risk of contracting cultureconfirmed S Typhi was 95% lower among vaccinated
children than among unvaccinated children. The quarterly
incidence of S Typhi after the vaccination campaign
(2018–19) was significantly lower than before the
vaccination campaign (2017); however, during the last
quarters of 2018 and 2019, incidence of S Typhi was higher
than in 2017. The most plausible explanation for the rise
in cases during this period could be the seasonality
of S Typhi, as higher numbers of cases—including
www.thelancet.com/lancetgh Vol 9 August 2021

outbreaks—occur during the monsoon period (May to
September), followed by sporadic cases during the rest of
the year. Although mass immunisation with Typbar-TCV
could substantially reduce the number of S Typhi cases
during the peak monsoon season, we did not observe a
noticeable decline outside of the peak monsoon season
in 2018–19. 3-year (2017–19) S Typhi surveillance data
with the same case definition from the adjacent city
of Karachi, Pakistan, where mass immunisation with
Typbar-TCV was not initiated until the end of 2019,
showed a significantly higher number of S Typhi cases
in all quarters of 2018–19 compared to 2017,3 further
demonstrating that the decline in the number of cases
during the monsoon periods of 2018–19 in Hyderabad,
Pakistan, was not an artifact of fewer rains or mild
monsoons during 2018–19 compared to 2017.
Limited data from the use of Typbar-TCV to control
a typhoid fever outbreak in Zimbabwe reported a
sharp decline in the number of culture-confirmed and
e1160
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suspected S Typhi cases among children aged 6 months
to 15 years after 3 months of the vaccination campaign.
The authors reported culture-confirmed S Typhi in
21% of cases before the vaccination campaign compared
to none after vaccination with Typbar-TCV.14 The study
from Zimbabwe did not report vaccine effectiveness
or a difference in incidence of S Typhi before and
after the vaccination campaign and hence cannot
be compared with our estimates. Furthermore, the
number of culture-confirmed S Typhi cases reported
from Zimbabwe was small (23 of 109 blood cultures
before the immunisation campaign and 0 of 24 blood
cultures afterwards), whereas in the present study
we established sentinel and laboratory surveillance,
and thousands of blood cultures were done to identify
culture-confirmed S Typhi. In the phase 3 randomised
controlled trial in Nepal, 20 019 children aged 6 months
to 16 years were enrolled and randomly assigned
to receive either a single dose of Typbar-TCV or the
meningococcal A vaccine; preliminary data reported a
1-year protective efficacy of TCV of 81·6% (95% CI
58·8–91·8) against culture-confirmed S Typhi.8 When
restricting the analysis to S Typhi cases confirmed by
blood culture among participants who presented with
fever for at least 3 days before blood culture testing,
the 1-year protective efficacy further increased to 85·1%
(95% CI 49·7–95·6). These results are consistent with
our findings from Hyderabad, Pakistan, where the case
definition included 3 days of fever before blood culture
testing and positivity for S Typhi. Likewise, data from a
double-blind, randomised, placebo-controlled trial of
children aged 2–5 years in Vietnam reported that two
doses of another typhoid conjugate vaccine (Vi bound
to non-toxic recombinant Pseudomonas aeruginosa
exotoxin A) had a protective efficacy of 91·5% (95% CI
77·1–96·6) against culture-confirmed S Typhi for
27 months.15 By contrast, a single-centre, phase 2b trial
based on an established human challenge model in the
UK enrolled 112 healthy volunteers aged 18–60 years
with no history of typhoid fever, typhoid vaccination, or
prolonged exposure in a typhoid-fever-endemic region,
and participants were either administered Typbar-TCV,
the Vi-polysaccharide vaccine, or the meningococcal
conjugate vaccine (control group); 1 month after vaccine
administration, all participants were exposed to S Typhi
via oral ingestion and closely assessed for the
development of typhoid fever (persistent fever ≥38°C
for at least 12 h or S Typhi bacteraemia). Based on this
study, Typbar-TCV was reported to have an effectiveness
of only 55% (95% CI 27–72).7 The potential explanation
for the relatively lower efficacy of Typbar-TCV in the
human challenge study done in the UK could be the
enrolment of adult participants from a non-endemic
setting without previous exposure to S Typhi and
applying a more sensitive case definition (including
S Typhi bacteraemia with or without clinical
manifestations), which might not be detectable in an
e1161

endemic setting. Another explanation for the low efficacy
could be the high challenge dose administered after the
neutralisation of gastric acid.
Although the findings of the phase 3 trial of Typbar-TCV
in Nepal have been reported,8 our study demonstrates
the real-world effectiveness of the vaccine in the context
of an outbreak response in an urban, low-income to
middle-income, typhoid-endemic setting. And although
the internal validity of randomised controlled trials is
important, the generalisability of the findings beyond the
study population is always debatable.16 Furthermore, the
confidence interval of the reported vaccine efficacy in the
randomised controlled trial done in Nepal was quite
wide, suggesting either low power of the study or a fewer
number of cases than expected. By contrast, our cohort
study in Hyderabad, Pakistan, was sufficiently powered
and thus our findings have greater generalisability and
policy implications. This study is also, to the best of our
knowledge, the first to report the impact of Typbar-TCV
against XDR S Typhi.
Key strengths of our study include the use of a cohort
study design, establishment of a baseline population
census registry, a tight surveillance system, uniform case
definition for confirmed and suspected cases, and a large
sample size, all of which increase not only the internal
but also external validity of our findings. Moreover, to our
knowledge this is the first study to report the effectiveness
of Typbar-TCV in children as young as 6 months.
This study provides important evidence that has impli
cations for vaccination campaigns to control typhoid fever
outbreaks. Furthermore, although Pakistan has suboptimal vaccination coverage for routine immunisation,17
the fact that this study showed a vaccine effectiveness
of more than 90% with a modest coverage of 57%
is reassuring for Pakistan and other countries facing
similar challenges relating to routine immunisation.
Furthermore, this study was done in an outbreak setting
where the predominant strain type was XDR, indicating
that Typbar-TCV can help counter antimicrobial resistance
and is presumably expected to have a concomitant impact
on mortality from typhoid fever as well.
This study had several limitations. First, clinicians
only started using blood culture as a diagnostic tool for
typhoid fever instead of serology in the face of the
XDR S Typhi outbreak, leading to ascertainment of a
higher number of culture-confirmed S Typhi cases, and
hence the change from serology-based to blood-culturebased diagnoses happened gradually, especially at the
start of the vaccination campaign, so our impact
assessment (comparing the incidence of S Typhi before
and after vaccination) might have been biased towards
the null, resulting in underestimation of the impact of
Typbar-TCV. Second, attendance for blood culture was
much lower among vaccinated than among unvaccinated
children. This is likely to be due to a vaccine-induced
reduction in disease burden, but it is plausible that
vaccination itself might confer improved confidence
www.thelancet.com/lancetgh Vol 9 August 2021
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in wellbeing and reduced treatment-seeking behaviour.
To mitigate this possibility, we enrolled children inde
pendently through the surveillance system without
ascertainment of their vaccination status at the time of
enrolment, provided a free-of-cost blood testing facility
for everyone who fulfilled the suspected case definition,
and involved the data management team to electronically
link vaccination records. Last, XDR status was unknown
for 48·9% of the vaccinated culture-confirmed S Typhi
cases, compared to 13·3% of unvaccinated cases. This
differential misclassification of unknown XDR status
(although unknown data were excluded during the
analysis) has the potential to bias our vaccine effectiveness
estimates against XDR S Typhi away from the null.
In conclusion, Typbar-TCV was effective against
culture-confirmed S Typhi among children aged 6 months
to 10 years in an outbreak setting in Pakistan and was
able, with only moderate deployment, to curtail a major
XDR S Typhi outbreak in a densely populated setting.
Our findings show that the vaccine is effective against
S Typhi irrespective of antimicrobial resistance.
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